Skip to main content
. Author manuscript; available in PMC: 2021 Aug 12.
Published in final edited form as: J Med Chem. 2020 Oct 23;63(21):12642–12665. doi: 10.1021/acs.jmedchem.0c00943

Figure 5.

Figure 5.

Enzalutamide-resistant LNCaP (MR49F) cellular antiproliferation. Enzalutamide (4)-resistant (Enz-R) LNCaP (MR49F) cells were plated in 1% charcoal-stripped, serum-containing medium and treated with 0.1 nM R1881 and a titration of antagonist as indicated in the figure. Cells were retreated 3 d after the first treatment and the number of viable cells was measured by the CellTiter-Glo assay (Promega, Madison, WI). N = 3.